OptimizeRx (NASDAQ:OPRX) Earns “Outperform” Rating from William Blair

William Blair reissued their outperform rating on shares of OptimizeRx (NASDAQ:OPRX) in a report issued on Thursday morning,RTT News reports.

Other equities research analysts have also recently issued reports about the stock. B. Riley initiated coverage on shares of OptimizeRx in a research report on Thursday, July 25th. They set a “buy” rating and a $18.50 price objective for the company. JMP Securities cut their price target on shares of OptimizeRx from $16.00 to $8.00 and set a “market outperform” rating for the company in a report on Thursday. Royal Bank of Canada decreased their price objective on OptimizeRx from $14.00 to $7.00 and set an “outperform” rating on the stock in a report on Thursday. Roth Mkm reissued a “buy” rating and set a $16.00 target price (down previously from $20.00) on shares of OptimizeRx in a research note on Thursday. Finally, Barclays reduced their target price on OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating on the stock in a research report on Thursday. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.42.

OptimizeRx Stock Down 5.7 %

Shares of NASDAQ:OPRX opened at $3.83 on Thursday. OptimizeRx has a 52-week low of $3.78 and a 52-week high of $16.65. The stock has a market cap of $70.17 million, a P/E ratio of -2.88 and a beta of 1.32. The business has a fifty day moving average of $6.60 and a two-hundred day moving average of $8.97. The company has a quick ratio of 3.07, a current ratio of 3.23 and a debt-to-equity ratio of 0.29.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets grew its stake in shares of OptimizeRx by 189.2% in the third quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock valued at $28,000 after buying an additional 2,414 shares in the last quarter. Connors Investor Services Inc. boosted its holdings in OptimizeRx by 15.1% during the 2nd quarter. Connors Investor Services Inc. now owns 19,107 shares of the company’s stock valued at $191,000 after acquiring an additional 2,500 shares during the period. Summit Securities Group LLC acquired a new position in OptimizeRx in the 2nd quarter valued at about $25,000. Rhumbline Advisers increased its stake in OptimizeRx by 9.2% during the second quarter. Rhumbline Advisers now owns 31,462 shares of the company’s stock worth $315,000 after purchasing an additional 2,658 shares during the period. Finally, Greenwood Capital Associates LLC lifted its position in shares of OptimizeRx by 8.0% during the third quarter. Greenwood Capital Associates LLC now owns 67,356 shares of the company’s stock worth $520,000 after purchasing an additional 4,999 shares in the last quarter. 76.47% of the stock is currently owned by institutional investors and hedge funds.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.